Cargando…

Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome

Sjögren’s syndrome (SS) is a chronic systemic inflammation disease with clinical presentation of dry eye, dry mouth, and polyarthralgia. Active inflammation is associated with an increased risk of associated arterial stiffness or subclinical atherosclerosis-related cardiovascular events. We used the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Deng-Ho, Wang, Yu-Hsun, Pan, Lung-Fa, Wei, James Cheng-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694056/
https://www.ncbi.nlm.nih.gov/pubmed/33126508
http://dx.doi.org/10.3390/jcm9113469
_version_ 1783614888630812672
author Yang, Deng-Ho
Wang, Yu-Hsun
Pan, Lung-Fa
Wei, James Cheng-Chung
author_facet Yang, Deng-Ho
Wang, Yu-Hsun
Pan, Lung-Fa
Wei, James Cheng-Chung
author_sort Yang, Deng-Ho
collection PubMed
description Sjögren’s syndrome (SS) is a chronic systemic inflammation disease with clinical presentation of dry eye, dry mouth, and polyarthralgia. Active inflammation is associated with an increased risk of associated arterial stiffness or subclinical atherosclerosis-related cardiovascular events. We used the longitudinal health insurance database of Taiwan, which includes one million participants, to evaluate the relationship between the clinical medication of hydroxychloroquine (HCQ) and the development of coronary artery disease (CAD). In total, 1674 patients with SS receiving HCQ medication were included after exclusion for previous CAD. Altogether, 1142 SS patients were included for evaluation after follow-up for more than one year. After adjusting for age, gender, medications, and chronic comorbidities, a significantly decreased hazard ratio (HR) for developing CAD was found among SS patients with higher medication possession ratio (MPR) of HCQ (HR = 0.49, 95% confidence interval, CI: 0.26–0.94) when compared with low MPR of HCQ. A low HR for CAD was observed in SS patients with a high cumulative dose of at least 100,267 mg of HCQ (HR = 0.25, 95% CI: 0.09–0.66). Long-term HCQ therapy may decrease the HR of CAD in SS patients. The significant cardiovascular protective effect of HCQ therapy was observed in our study.
format Online
Article
Text
id pubmed-7694056
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76940562020-11-28 Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome Yang, Deng-Ho Wang, Yu-Hsun Pan, Lung-Fa Wei, James Cheng-Chung J Clin Med Article Sjögren’s syndrome (SS) is a chronic systemic inflammation disease with clinical presentation of dry eye, dry mouth, and polyarthralgia. Active inflammation is associated with an increased risk of associated arterial stiffness or subclinical atherosclerosis-related cardiovascular events. We used the longitudinal health insurance database of Taiwan, which includes one million participants, to evaluate the relationship between the clinical medication of hydroxychloroquine (HCQ) and the development of coronary artery disease (CAD). In total, 1674 patients with SS receiving HCQ medication were included after exclusion for previous CAD. Altogether, 1142 SS patients were included for evaluation after follow-up for more than one year. After adjusting for age, gender, medications, and chronic comorbidities, a significantly decreased hazard ratio (HR) for developing CAD was found among SS patients with higher medication possession ratio (MPR) of HCQ (HR = 0.49, 95% confidence interval, CI: 0.26–0.94) when compared with low MPR of HCQ. A low HR for CAD was observed in SS patients with a high cumulative dose of at least 100,267 mg of HCQ (HR = 0.25, 95% CI: 0.09–0.66). Long-term HCQ therapy may decrease the HR of CAD in SS patients. The significant cardiovascular protective effect of HCQ therapy was observed in our study. MDPI 2020-10-28 /pmc/articles/PMC7694056/ /pubmed/33126508 http://dx.doi.org/10.3390/jcm9113469 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yang, Deng-Ho
Wang, Yu-Hsun
Pan, Lung-Fa
Wei, James Cheng-Chung
Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome
title Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome
title_full Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome
title_fullStr Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome
title_full_unstemmed Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome
title_short Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome
title_sort cardiovascular protection of hydroxychloroquine in patients with sjögren’s syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694056/
https://www.ncbi.nlm.nih.gov/pubmed/33126508
http://dx.doi.org/10.3390/jcm9113469
work_keys_str_mv AT yangdengho cardiovascularprotectionofhydroxychloroquineinpatientswithsjogrenssyndrome
AT wangyuhsun cardiovascularprotectionofhydroxychloroquineinpatientswithsjogrenssyndrome
AT panlungfa cardiovascularprotectionofhydroxychloroquineinpatientswithsjogrenssyndrome
AT weijameschengchung cardiovascularprotectionofhydroxychloroquineinpatientswithsjogrenssyndrome